HIMS Chief Policy Officer Deborah Autor Sells 3,656 Shares
Deborah Autor, Chief Policy Officer at Hims & Hers Health, sold 3,656 shares on June 11, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Deborah Autor, Chief Policy Officer at Hims & Hers Health, Inc. ($HIMS), sold 3,656 shares on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $HIMS is up 22.9% after 1 week, up 19.1% after 1 month and down 2.8% to date (from the $28.87 close on Jun 11, 2026).
HIMS
Hims & Hers Health, Inc.
Key Points
- On June 11, 2026, Deborah Autor sold 3,656 shares of Hims & Hers Health, Inc. at a price of $26.82, totaling approximately $97,000.
- The stock is currently trading around $26.82, which is above its 52-week low of $13.74 but well below its 52-week high of $57.45.
- Analysts maintain a consensus 'Hold' rating on Hims & Hers Health, with a target price averaging $31.15.
Get $HIMS trade alerts by text
We text you when insiders, Congress or big funds trade $HIMS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hims & Hers Health, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Hims & Hers Health, Inc.
On June 11, 2026, Deborah Autor, the Chief Policy Officer at Hims & Hers Health, Inc. (NYSE: HIMS), sold 3,656 shares at a price of $26.82. This transaction is valued at approximately $97,000. Autor's sale follows another significant insider transaction on June 15, where she sold 15,396 shares, indicating active insider trading in the company.
Institutional Activity
No other institutional activity data is available for this report. However, it's worth noting that Hims & Hers Health has been under the radar of various analysts.
How Hims & Hers Health, Inc. Stock Has Traded
Currently, Hims & Hers Health stock trades around $26.82, which represents a considerable drop from its 52-week high of $57.45. The stock is performing well above its 52-week low of $13.74, suggesting some resilience in its market position despite recent insider selling.
Recent Earnings
Hims & Hers Health reported revenue of approximately $2.58 billion, with a revenue growth rate of 38.2%. However, the company is currently not profitable, with an EPS of -0.64. The next earnings report is scheduled for November 9, 2026.
Insider Buying and Selling at Hims & Hers Health, Inc.
In addition to Deborah Autor's recent sale, Chief Legal Officer Soleil Boughton sold 42,261 shares on June 15, 2026. Meanwhile, CTO Mohamed Elshenawy acquired 282,597 shares on the same date, indicating mixed signals from the company's leadership. Notably, David Wells and Delos Cosgrove both sold 3,656 shares on June 11, 2026, on the same day as Autor's transaction.
Analysts Set New Price Targets
Analysts are maintaining a cautious outlook on Hims & Hers Health. On August 24, 2026, Truist Securities maintained a 'Hold' rating with a target price of $32. Meanwhile, Barclays also kept its 'Overweight' rating with a target of $35. The consensus target price among 13 analysts stands at $31.15, suggesting a mixed sentiment in the market.
What Hims & Hers Health, Inc. Does
Hims & Hers Health, Inc. is a consumer-focused health and wellness platform that connects individuals with licensed healthcare providers. The company offers a variety of prescription and non-prescription products and services, focusing on areas like skincare, sexual health, and mental wellness. This recent insider activity highlights potential shifts in confidence among its leadership as the company navigates its growth trajectory.
What's Next for Hims & Hers Health, Inc.
Investors will be watching for the next earnings report on November 9, 2026, to gauge the company's performance and outlook. The recent insider sales reflect past holdings and may not represent current positions, but they are worth monitoring as Hims & Hers Health continues to expand its market presence.
Related Filing Alerts
Source: Deborah Autor's Form 4 filing on $HIMS (Jun 11, 2026). Find the original filing: HIMS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts